FDA Warnings And Restrictions On JAKs Curb Growth Potential Of Big Brands

 
• By Jessica Merrill

Pfizer, AbbVie and Lilly will face new safety restrictions on Xeljanz, Rinvoq and Olumiant. Indication expansion remains uncertain, while first-line use appears out of the question.

Caution tape
FDA put new warnings on JAK inhibitors for inflammatory conditions • Source: Alamy

More from Immunological

More from Therapy Areas